Market Open

It’s a muted open on both sides of the border as investors hold back ahead of Powell’s Friday spotlight at Jackson Hole.

Market Numbers (Futures)

TSX : Down ( 0.02%) 27,818.32
TSXV: Down (1.94%) 773.80
DOW:  Down (0.10%) 45,953.00
NASDAQ: Down (0.29%) 23,400.00
FTSE: Up (0.40%) 9,226.55

In the Headlines:

Canaccord Genuity is expanding down under, snapping up Wilsons Advisory in a move that could reshape its presence in Australian wealth and capital markets.

And Pierre Poilievre storms to an 80% win in the Alberta byelection, clearing the way for his high-profile return to Parliament this fall

Currencies Update: (Futures)

The Canadian dollar barely budged against the greenback, drifting 0.01% to US$0.7208, managed a hair of strength against the euro by 0.03% to $$0.6191, while Bitcoin took a beating, sliding nearly 1.74% to hover at CDN$157,589.61.

Commodities: (Futures)

Natural Gas: Down (1.57%), 2.73
WTI:  Up (0.16%), 62.45
Gold: Up (0.56%), 3,333.96
Copper:  Up (0.11%) 6.02

To stay up-to-date on all of your market news head to stockhouse.com

Join the discussion: Find out what everybody’s saying check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here

More From The Market Online
TSX edges higher as La Caisse buys Optio, Nvidia gains on OpenAI financing and D-Wave jumps on quantum demand. Oil drops, gold rises and Bitcoin firms

Market Open: La Caisse Buys Optio, Nvidia Gains on OpenAI Financing | July 27th

TSX edges higher as La Caisse buys Optio, Nvidia gains on OpenAI financing and D-Wave jumps on quantum demand. Oil drops, gold rises and…

Skyward bound: ZenaTech’s scaling drone growth story

Discover why ZenaTech is emerging as a drone industry leader through AI-powered DaaS, strategic M&A, defense upside and rapid revenue growth.

A small-cap contender looking to challenge the weight-loss drug giants

Structure Therapeutics (NASDAQ:GPCR) is developing an oral weight-loss pill that could offer an alternative to popular injectable treatments.